Anavex Life Sciences Corp. financial data

Symbol
AVXL on Nasdaq
Location
630 5 Th Avenue, 20 Th Floor, New York, NY
Fiscal year end
September 30
Latest financial report
10-K - Q3 2025 - Nov 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.8 % +36.1%
Return On Equity -46.8 % -41.6%
Return On Assets -41.5 % -37.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89.3M shares +5.34%
Common Stock, Shares, Outstanding 86.7M shares +2.21%
Entity Public Float 708M USD +71.8%
Common Stock, Value, Issued 87K USD +2.35%
Weighted Average Number of Shares Outstanding, Basic 85.3M shares +2.18%
Weighted Average Number of Shares Outstanding, Diluted 85.3M shares +2.18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 37.6M USD -10.1%
General and Administrative Expense 13.8M USD +25.2%
Operating Income (Loss) -51.4M USD +2.78%
Nonoperating Income (Expense) 5.03M USD -49.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43M USD +9.47%
Net Income (Loss) Attributable to Parent -46.4M USD -7.85%
Earnings Per Share, Basic 0 USD/shares -3.85%
Earnings Per Share, Diluted 0 USD/shares -3.85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 103M USD -22.4%
Assets 104M USD -23.4%
Accounts Payable, Current 4.25M USD -55.9%
Accrued Liabilities, Current 3.89M USD -19.5%
Liabilities 8.95M USD -41.5%
Retained Earnings (Accumulated Deficit) -382M USD -13.8%
Stockholders' Equity Attributable to Parent 94.9M USD -21.1%
Liabilities and Equity 104M USD -23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -65.6%
Net Cash Provided by (Used in) Financing Activities 708K USD +1100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 86.7M shares +2.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 103M USD -22.4%
Deferred Tax Assets, Valuation Allowance 108M USD +17.6%
Deferred Tax Assets, Gross 20.7M USD +37.1%
Deferred Tax Assets, Operating Loss Carryforwards 54.8M USD +13.7%
Current Income Tax Expense (Benefit) 59K USD -79%
Preferred Stock, Shares Authorized 10M shares 0%
Share-based Payment Arrangement, Expense 11.5M USD +22.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%